Ibrutinib is typically used to treat patients who have received at least one prior therapy. Ibrutinib is an anticancer (antineoplastic) drug that belongs to a class of medications known as tyrosine kinase inhibitors which work by blocking the activity of tyrosine kinases, a family of enzymes that ...
Uses of Ibrutinib Ibrutinib is an oral, potent, selective and irreversible small molecule inhibitor of Btk. It is a prescription drug with the trade name IMBRUVICA®. It is approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prio...
(BTK) inhibitor, which is a first-in-class innovative drug. It was granted breakthrough therapy designation by the FDA in February 2013 and approved for the treatment of MCL and chronic lymphocytic leukemia (CLL) on November 13, 2013, and February 12, 2014, respectively. This drug ...
Class 2 ring heterocyclic compounds; Antiallergics; Antineoplastics; Antirheumatics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors Orphan Drug Status Yes - Chronic lymphocytic...
Drug Interactions: No data available. Therapeutic Indications in Hematology: Ibrutinib is used in CLL/small lymphocytic lymphoma, MCL, diffuse large B-cell lymphoma, and MM. It is approved for the treatment of MCL patients who have received two prior therapies and CLL patients with the 17p dele...
Find information on Ibrutinib (Imbruvica) in Davis’s Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
Ibrutinib (PCI-32765) is a novel, orally active, irreversible inhibitor of BTK that has demonstrated considerable efficacy in a variety of B-cell malignancies. The US Food and Drug Administration (FDA) formally designated ibrutinib as a breakthrough therapy, and it was approved for the treatment...
Ibrutinib is a first-in-class inhibitor of Bruton's tyrosine kinase, developed specifically for the treatment of B-cell cancers, including CLL. The drug has shown "striking" efficacy in both indications, and has stirred up considerable excitement in hematology circles, with experts describing it ...
Relevant published information was not found as of the revision date. Substance Identification Substance Name Ibrutinib CAS Registry Number 936563-96-1 Drug Class Breast Feeding Lactation Milk, Human Antineoplastic Agents Enzyme Inhibitors Protein Kinase Inhibitors ...
Ibrutinib (Imbruvica, Pharmacyclics, Janssen) is the first-in-class irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is positioned downstream of the BCR at the cell surface of normal and malignant B-cells. In 2013, the Food and Drug Administration (FDA) granted accelerated ...